ABSTRACT Background: Diet is an important factor in colorectal carcinogenesis; thus, dietary supplements may have a role in colorectal cancer prevention. Objective: The objective was to establish the relative luminal, epithelial, and epigenetic consequences of prebiotic, probiotic, and synbiotic dietary supplementation in humans. Design: This was a randomized, double-blind, placebo-controlled, 4-wk crossover trial of resistant starch and Bifidobacterium lactis, either alone or as a combined synbiotic preparation, in 20 human volunteers. Rectal biopsy, feces, and serum samples were collected. The rectal mucosal endpoints were DNA methylation at 16 CpG island loci and LINE-1, epithelial proliferation (Ki67 immunohistochemistry), and crypt cellularity. The fecal endpoints were short-chain fatty acid concentrations, pH, ammonia, and microbiological profiles (by denaturing gradient gel electrophoresis and sequencing). Serum endpoints were a panel of cytokines and high-sensitivity C-reactive protein.
INTRODUCTION
Diet is extremely important in colorectal carcinogenesis, with the colorectal lumen being a crucial link between diet and epithelial biology (1) (2) (3) (4) (5) . Diets rich in cruciferous vegetables and fiber are associated with many beneficial luminal events that help to reduce colorectal cancer (CRC) risk (1) (2) (3) (4) (5) . Dietary fiber increases stool bulk, which in turn dilutes, binds, and hastens the transit of carcinogens within the alimentary tract (2) . Dietary fiber is an effective prebiotic, promoting many beneficial microbial communities (2, 6, 7) . Specific bacteria within the proximal colon also ferment undigested fiber to generate beneficial short-chain fatty acids (SCFAs), such as acetate and butyrate (8) . In CRC cell lines, butyrate enhances cellular differentiation and reduces proliferation (8, 9) . In human studies, butyrate and the associated lowering of luminal pH are associated with a reduced risk of CRC (2, 10, 11). Butyrate's effects on cellular biology are mediated in part through its activity as a histone deacetylase inhibitor (2) , which can regulate the expression of many critical cell cycle regulators, such as CDKN1A (12) (13) (14) . Whereas butyrate can increase global histone acetylation, it may also induce the deacetylation of certain histones, which causes a more targeted transcriptional repression (13) . The epigenetic influence of butyrate now extends beyond chromatin remodeling to include DNA methylation (15) .
Animal carcinogenesis models have translated these luminal and molecular events into biological outcomes. In carcinogentreated rats, the addition of resistant starch (RS), in part mediated through increased SCFA production, protects against intestinal tumorigenesis, ameliorates mucosal DNA damage, and augments apoptosis (16) (17) (18) (19) (20) (21) . In human studies, RS has been shown to reduce colorectal epithelial proliferation (22, 23) .
Some probiotic therapies, in which viable microorganisms are directly administered to the host, have also been associated with important clinical benefits, particularly in conditions characterized by gastrointestinal dysbiosis, such as antibiotic-associated diarrhea, necrotizing enterocolitis, and recurrent pouchitis (24) (25) (26) . Probiotics may influence the colonic lumen through their direct metabolic output and through their interaction with resident flora and host immunity (24) .
More recently, many studies have investigated the coadministration of prebiotics with probiotics, so-called synbiotics. Synbiotics may help to enhance colonic fermentation and promote a healthy colorectal environment beyond that afforded by pre-or probiotic supplementation alone (24, 27) . Starch is the preferred substrate for Bifidobacterium lactis. In carcinogentreated rats, the combination of RS and B. lactis significantly increased apoptosis beyond that of its individual components (28) . A recent synbiotic intervention in patients with a history of colorectal neoplasia was associated with a reduction in rectal epithelial proliferation, modulation of cytokine production [interleukin-2 (IL-2) and interferon-c], promotion of beneficial bacterial communities, and a reduction in DNA damage within the rectal epithelial cells (29) . The exact colorectal value of the synbiotic combination, relative to the pre-and probiotic components alone, however, was not tested.
We performed a randomized, double-blind, placebo-controlled, crossover trial of RS-containing high-amylose maize starch (HAMS) and B. lactis, either alone or as a combined synbiotic preparation, in 20 human volunteers. This study characterized the luminal and biological consequences of these supplements and placed them in the context of colorectal carcinogenesis.
SUBJECTS AND METHODS

Study design
The study was a double-blind, randomized, placebo-controlled, crossover trial that compared dietary supplementation with prebiotic alone, probiotic alone, or a combined synbiotic intervention. Each intervention lasted 4 wk without a washout period, in keeping with earlier studies (30) . Twenty healthy subjects aged 21-75 y took part in the study. Subjects with a history of inflammatory bowel disease, CRC, or recent antibiotic or anticoagulation therapy, were not permitted in the study. All subjects stopped any probiotic or prebiotic supplements (including yogurt and fermented beverages) 4 wk before and for the duration of the study. The subjects were randomly assigned to 1 of 6 sequential 4-wk intervention protocols ( Table 1) .
Each day, the subjects received, in a double-blinded fashion, one sachet and one capsule to supplement their usual diet. The active and inactive formulations were identically packaged. The 4-wk prebiotic intervention consisted of 25 g HAMS/d (one sachet containing Hi-maize 958, '12.5 g RS; National Starch Food Innovation, Sydney, Australia) (31) (32) (33) (34) (35) and placebo probiotic (one capsule containing 5 g sucrose). The probiotic intervention was one capsule containing 5 g B. lactis (LAFTI B94 at 10 9 colony-forming units/g; DSM Food Specialties, Sydney, Australia) plus placebo starch (one sachet containing 25 g digestible maize cornstarch, ,0.2 g RS; National Starch Food Innovation) (32) , and the synbiotic supplement was a combination of both active supplements. The study was approved by the institutional review board, and all volunteers gave written informed consent. 
Sampling
Tissue, serum, feces, and questionnaire responses were collected at baseline (after the 4-wk washout period) and then at the end of each 4-wk intervention (Table 1) . Serum was stored at 280°C until processed. Two days before each study visit, there was a 24-h fecal collection. The feces were stored at 220°C within a portable freezer until transfer to the laboratory freezer (220°C). At each visit, a gastroenterologist (DLW) performed a proctoscopy and collected 4 rectal mucosal biopsies. Two biopsies were snap frozen in liquid nitrogen and stored at 280°C
, and the remainder was formalin-fixed and embedded in paraffin blocks.
Fecal samples
Microbiology. The stool bacterial community was characterized by denaturing gradient gel electrophoresis (DGGE) followed by sequencing of major bands. Fecal DNA was amplified by using universal bacterial 16S rRNA primers and polymerase chain reaction (PCR) conditions, as described previously (7, 36) . The PCR product was examined by DGGE (Ingeny International, Goes, Netherlands) and stained with Syber-gold nucleic acid stain (Molecular Probes, Eugene, OR) (7) . A fecal control sample ensured consistent DGGE banding patterns ( Figure 1 ). DNA was extracted from the dominant DGGE bands by using a modification of the method described by Boom et al (36) . First, the DGGE bands were excised from the gels by using an x-tracta (Geneworks, Hindmarsh, South Australia, Australia), submerged in diffusion buffer (0.5 mol ammonium acetate/L, 10 mmol magnesium acetate/L, and 1 mmol EDTA/L, pH 8.0; 0.1% sodium dodecyl sulfate) and incubated at 50°C for 30 min. The extraction otherwise followed the modifications of Abell et al (7) . The extracted DNA was reamplified by using the same primers without the GC-clamp and sequenced in both the forward and reverse direction by capillary separation on an AB 3730xl sequencer. The sequences were checked and assembled by using ChromasPro version 1.41 (Technelysium Pty Ltd, Tewantin, Australia). The complete sequences were putatively identified by using Basic Local Alignment Search Tool (BLAST) and GenBank (37) . DGGE banding patterns for each specimen were further analyzed by a density matrix in the GelCompar II version 5.10 (Applied Maths Inc, Austin, TX).
B. lactis was quantified by real-time PCR with a 1 · IQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA), 600 nmol primer/L, Bflact2F (GTGGAGACACGGTTTCCC), Bflact5R (CACACCACACAATCCAATAC) (38) , and 0.2 mg bovine serum albumin/mL in a Chromo-4 thermocycler (Bio-Rad Laboratories, Hercules, CA). The results were analyzed by Opticon Monitor 3 software (version 3.1; Bio-Rad Laboratories). The PCR conditions for B. lactis were 95°C hot start for 5 min, then 35 cycles of 95°C for 30 s, 60°C for 1 min, and 72°C for 1 min. B. lactis was reported both qualitatively and quantitatively as B. lactis per gram of feces (wet weight).
Short-chain fatty acids. Fecal samples were homogenized in 3 volumes of internal standard solution (1.68 mmol heptanoic acid/L) and centrifuged. The supernatant fluid was vacuum distilled, and 0.2 lL of each distillate was loaded onto a Zebron ZB-FFAP (Phenomenex) gas chromatography (GC) column within an Agilent 6890N Network GC system, as described elsewhere (7). The concentrations of acetic, butyric, isobutyric, valeric, isovaleric, propionic, and caproic acids and total SCFAs are reported in mmol/L.
Ammonia and pH. Fecal ammonia concentrations (mg/g feces) were measured by calorimetry by using an ammonia assay kit (Sigma-Aldrich, St Louis, MO). To determine fecal pH, the feces was homogenized in 3 volumes of saline, and the pH was recorded with a digital meter (digital pH meter, model 1852mV; TPB, Brisbane, Australia).
Serum
Serum cytokine concentrations for IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, granulocyte-macrophage colony stimulating factor, interferon-c, and tumor necrosis factor-a were quantified by using the Lincoplex high-sensitivity human cytokine kit (Linco, St Charles, MO), according to the manufacturer's instructions. Multianalyte profiling was performed on the Luminex-200 system, and fluorescence data were analyzed with the Liquichip system (version 1.0.5; Qiagen, Doncaster, Australia).
Serum high-sensitivity C-reactive protein was analyzed on a Hitachi Cobas-Bio modular analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan) by using a Tina-quant C-reactive protein (latex) high-sensitive assay kit (Roche Diagnostics, Mannheim, Germany).
Rectal biopsies
Proliferation index and crypt height. Two rectal biopsy specimens were formalin-fixed and embedded in paraffin. Ki67 immunohistochemistry was performed by using standard techniques ( Figure 2) . Briefly, deparaffinized 5-lm sections were rehydrated in graded ethanol baths. After antigen retrieval, monoclonal mouse anti-Ki67 primary antibody (M7248; DakoCytomation, Glostrup, Denmark) was added (1/1000 dilution) and incubated overnight at 4°C. A level 2 Ultra Streptavidin detection system was used (Signet Laboratories Inc, Dedham, MA). The slides were counterstained with hematoxylin. Crypt heights were reported as the mean number of cells per crypt column (20 complete crypt columns counted per sample). The proliferation index was calculated as the percentage of Ki67-stained cells as a proportion of total cells within the crypt column, reported as a mean proliferation index (%) (Figure 2) . DNA methylation. DNA from the fresh frozen rectal mucosal biopsy specimens was extracted, purified, and bisulfite-modified by using the AllPrep DNA/RNA Mini and EpiTect Bisulfite Kits (Qiagen, Hilden, Germany), respectively. DNA methylation was quantified at 16 gene promoter regions. This included "type A" genes, in which considerable methylation is observed even in normal tissue related to aging (ESR1, GATA5, HIC1, HPP1, and SFRP1) (39-43), and "type C" markers, in which promoter methylation is more specific for neoplastic tissue (MLH1, CDKN2A, MINT1, MINT2, MINT31, CACNA1G, IGF2, RUNX3, NEUROG1, SOCS1, and MGMT) (44) (45) (46) (47) (48) . Methylation was quantified by using MethyLight-a methylation-specific, probebased, real-time PCR technique adapted from a published method (45) . Briefly, each reaction consisted of methylationspecific forward and reverse primers and probe (ABsolute QPCR Mix; ABgene, Epsom, United Kingdom), PCR-grade water and a 1:8 dilution of the EpiTect Bisulfite Kit elution. The PCR conditions, primers, and probe details are outlined elsewhere (see Supplementary Table 1 under "Supplemental data" in the online issue). Each run included a 5-point standard curve composed of serial dilutions of M.SssI-treated, bisulfite-modified human genomic DNA (M0226S; New England Biolabs, Beverly, MA). All samples were run in duplicate, except for standard 5, which was run in triplicate. Each run included one nontemplate control. All runs and analyses were performed by using a Rotor Gene 3000 real-time PCR machine and software (Qiagen, Hilden, Germany). The C(t) value for each sample was used to generate a calculated concentration. Alu was used as the methylation-independent normalization control reaction (45) . DNA methylation was reported as a percentage of methylated reference (PMR) = 100 · [(methylated reaction/Alu) sample / (methylated reaction/Alu) M.SssI-reference ] (45). Methylation was also quantified at LINE-1, which has been correlated with global DNA methylation and associated with chromosomal instability (50) . LINE-1 methylation was analyzed by pyrosequencing with the PyroMark kit (Biotage, Uppsala, Sweden) and the PSQ HS 96 System (Biotage), as previously described (49) . LINE-1 methylation was reported as the mean percentage of methylated cytosines across the 4 CpG sites (49) .
Questionnaire
Each subject completed a 6-part questionnaire regarding general well-being and gastrointestinal-specific symptoms at each time point (see Supplementary Table 2A and 2B under "Supplemental data" in the online issue). The questionnaire was adapted from a validated gastrointestinal quality of life index (50) .
Statistical analyses
The DGGE banding patterns were analyzed with Primer6 version 6.1.5 (Plymouth Marine Laboratory, Plymouth, United Kingdom) by using the Bray-Curtis similarity matrix and one- 
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factor multivariate analysis of similarity, as described (7) . Relations between the various factors, such as diet, sampling weeks, and the DGGE banding patterns, were examined. The treatment effect for all of the other variables was determined by using a mixed-model analysis of variance to assess the effect of period, treatment, and sequence of intervention (SAS 9.1; SAS Institute Inc, Cary, NC). The analysis compared each of the randomized interventions: synbiotic, probiotic, and probiotic. In addition, baseline fecal total SCFAs, butyrate, and pH were compared with a mean postintervention result with the Wilcoxon's signed-rank test. Correlations between normally distributed variables were analyzed by using Pearson's correlation coefficients (Stata Statistical Software, version 10; StataCorp, College Station, TX), Bonferroni-corrected for multiple comparisons.
RESULTS
Patients
Thirteen men and 7 women volunteered for the study. Their mean age was 60.4 y, ranging from 45 to 75 y (Table 1) . Seventeen of the 20 subjects completed the entire study. Subject 5 declined to have further rectal biopsy specimens collected after the second sampling, but continued with the rest of the study. Subjects 15 and 16 withdrew after the second and baseline sampling, respectively. Consequently, 20 subjects were sampled at baseline, 19 after the B. lactis-only intervention, and 18 after the HAMS-only and synbiotic interventions. For those who completed the study, there was 100% compliance with the dietary intervention. The baseline results are presented elsewhere (see Supplementary Table 3 under "Supplemental data" in the online issue), whereas the results after each randomized intervention are presented in Table 2 and Table 3 .
Stool microbiology
Bacterial DNA was extracted from the 75 available stool samples and analyzed by DGGE (Figure 1) . Overall, there were 136 different bacterial phylotypes identified. Interestingly, the bacterial profile of subjects after the synbiotic intervention was significantly different from the profile found after either the HAMS (R = 0.07, P = 0.032) or B. lactis (R = 0.18, P = 0.001) intervention alone.
No significant differences, however, were observed in the bacterial profile between the HAMS and B. lactis interventions (R = 20.01, P = 0.49), and no significant differences in DGGE profiles were observed between the intervention periods (see Supplementary Table 4 under "Supplemental data" in the online issue). Sequencing of the major bands showed that the differences between the interventions were related, in part, to a higher proportion of patients with Lachnospiraceae spp., particularly clone MS146A1_G07: 61% of subjects after the synbiotic intervention compared with 50%, 32%, and 45% after the HAMS, B. lactis, and baseline time points, respectively (see Supplementary Table 5 under "Supplemental data" in the online issue).
With the real-time PCR technique, B. lactis was, as expected, more commonly isolated from feces after probiotic-containing interventions (probiotic only: 71%; synbiotic: 53%) than at baseline (38%) or in the HAMS-only intervention (40%). Furthermore, in patients with fecal B. lactis, there were relatively higher quantities after the probiotic (8.8 · 10 7 B. lactis/g feces) and synbiotic (5.4 · 10 7 B. lactis/g feces) interventions than after the HAMS-only intervention (1.9 · 10 7 B. lactis/g feces) or at baseline (1.4 · 10 7 B. lactis/g feces).
Stool chemistry
At baseline, the mean stool pH was 7.4, and stool SCFA concentrations were comparable with those of other healthy populations (8, 10) . No significant, intervention-related differences in stool pH, fecal ammonia, or any of the individual or total SCFA concentrations were observed (Table 2) . Furthermore, mean stool SCFA concentrations and pH values averaged across all 3 intervention time points were unchanged from baseline (see Supplementary Figure 1 under "Supplemental data" in the online issue).
Serum inflammatory markers
There were no significant intervention-related differences in high-sensitivity C-reactive protein or in any of the individual serum cytokine concentrations (Table 2) .
Epithelial variables
Neither crypt proliferation nor cell height was significantly associated with dietary intervention (Table 3 ). To explore the interaction between epithelium and luminal components, we analyzed baseline total SCFA concentrations, proliferation index, and crypt height, corrected for multiple comparisons. At baseline, there was a significant inverse correlation between total SCFA concentration and crypt height (R = 20.56, P = 0.038; Figure  3A ) as well as an inverse trend between total SCFA concentration and the epithelial proliferation index (R = 20.50, P = 0.086; Figure 3B ). There was no significant correlation between crypt height and the epithelial proliferation index (R = 0.49, P = 0.10; Figure 3C ).
Mucosal DNA methylation
The type A markers had a much higher level of methylation in the normal rectal mucosa than did the type C markers (Table 3) . This was in keeping with earlier studies (48) . MINT2 was the only type C marker that had a mean PMR .1, and MINT2 was the methylation marker associated with a significant treatment effect (P = 0.040; Table 3 ). The synbiotic intervention was associated with the lowest mean mucosal MINT2 PMR ( Table 3 ).
The multiple analyses in this study, however, and the fact that no other methylation markers varied with dietary intervention made it likely that the significant dietary association with MINT2 methylation was due to chance alone. The mean LINE-1 methylation was 73% at baseline and did not show any significant change with dietary intervention.
Questionnaire
The study was very well tolerated (see Supplementary Table 2 under "Supplemental data" in the online issue). Interestingly, .60% (11/18) of the subjects after the RS-containing interventions reported that they were troubled by excessive flatus, a symptom of colonic fermentation, in contrast with '25% of subjects at baseline (4/20) or after the B. lactis only intervention (5/19) .
DISCUSSION
This was the first human study to compare the relative luminal, epigenetic, and epithelial consequences of prebiotic, probiotic, and synbiotic supplements. The synbiotic intervention of HAMS and B. lactis fostered a unique fecal stream bacterial community (see Supplementary Table 5 under "Supplemental data" in the online issue). The difference in fecal flora was in part explained by a greater proportion of patients harboring fecal Lachnospiraceae spp. A recent Apc Min mouse experiment found that colonic Lachnospiraceae spp. was protective against intestinal tumorigenesis (51) . The significant microbiological differences after the synbiotic intervention support the rationale that the combination of a prebiotic with a probiotic promotes luminal consequences beyond that of its individual components.
The dietary interventions significantly altered MINT2 methylation within the rectal mucosa, and synbiotic supplementation was associated with the very lowest MINT2 PMR 1.5. Low-level methylation of certain type C markers within normal colorectal mucosa may be important in early colorectal carcinogenesis, possibly as a foundation for future genetic and more advanced epigenetic events (46, 52, 53) . Whereas MINT2 does not correspond to a known gene, it remains an important methylation marker in CRC, particularly in the recently described CpG island methylator phenotype 2 class of CRC (48) . Butyrate has been shown to lower promoter methylation in CRC cell line studies (15) , but no significant effect of the dietary interventions on fecal SCFA concentrations was observed in our study. Given the multiple analyses and that there were no other dietary-related methylation events; however, it is likely that the association between MINT2 and intervention was related to chance alone. Nevertheless, the interface between diet and mucosal epigenetics remains an exciting topic for future colorectal carcinogenesis research.
One particularly important negative result was that fecal SCFA concentrations did not change between interventions or even when compared with baseline. Prebiotics, such as RS, indisputably increase SCFA concentrations and lower luminal pH in animal studies (8) . Human intervention studies, however, have reported mixed results with dose, preparation, and colonic transit, all important factors when estimating luminal SCFAs by fecal analysis (8) . Butyrate concentrations in the proximal colon can reach 100 mmol/L, but butyrate is rapidly used by colonocytes and declines throughout the distal colorectum (24) . The troublesome flatus reported by many of the subjects after the RS-containing interventions is consistent with altered colonic fermentation, even in the absence of any detectable change in fecal chemistry. Several human studies have reported increased fecal SCFA concentrations after RS-enriched diets (22, 30, 54) . These diets, however, have often involved larger doses of RS or the RSsupplementation occurred in the context of total dietary intake rather than simply as a supplementation to the subject's usual diet (8, 22, 30, 54, 55) . Other studies, however, similarly failed to show any significant changes in fecal pH and SCFAs (8) . It is quite possible that the 25 g HAMS/d used in our study contained insufficient RS ('12.5 g/d) to increase fecal SCFA concentrations (56) . Future human supplementation trials would be well advised to increase the scheduled daily dose of RS to 20 g/d (22, 23, 29) , particularly given that our supplementation protocol was relatively well tolerated.
The dietary interventions in this study had no significant effect on epithelial proliferation or crypt height, despite reports supporting an association (8, 22) . In contrast with our study, however, most of these trials reported significant increases in fecal SCFAs, and it is likely that our study failed to show an association between dietary intervention and epithelial proliferation because the dietary intervention did not sufficiently alter luminal chemistry. This finding was supported by the inverse correlation that we found between the baseline total fecal SCFA concentration and the proliferation index ( Figure 3 ) and with other reports (57) (58) (59) . This study confirmed that the synbiotic preparation of B. lactis (5 · 10 9 colony forming units/d) and HAMS (25 g/d) given over 4 wk generated a significantly different fecal bacteria profile when compared with either HAMS or B. lactis supplementation alone, even in the absence of other significant luminal events. The mechanisms underlying the microbial consequences of synbiotic interventions are worth exploring, particularly with regard to their implications for early colorectal carcinogenesis.
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